Literature DB >> 16498509

Matrix metalloproteinases in cardiovascular disease.

Peter Liu1, Mei Sun, Sawsan Sader.   

Abstract

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that are regulated by inflammatory signals to mediate changes in extracellular matrix. Members of the MMP family share sequence homology, act on interstitial protein substrates, acutely participate in inflammatory processes and chronically mediate tissue remodelling. MMPs are important in vascular remodelling, not only in the overall vasculature architecture but also, more importantly, in the advancing atherosclerotic plaque. MMP activation modifies the architecture of the plaque and may directly participate in the process of plaque rupture. MMPs also participate in cardiac remodelling following myocardial infarction and development of dilated cardiomyopathy. Soluble MMPs are now potential biomarkers in delineating cardiovascular risk for plaque rupture and coronary risk. They also constitute innovative direct or indirect targets to modify cardiovascular tissue remodelling in atherosclerosis and heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498509      PMCID: PMC2780831          DOI: 10.1016/s0828-282x(06)70983-7

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  25 in total

1.  Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury.

Authors:  Wenjie Wang; Costas J Schulze; Wilma L Suarez-Pinzon; Jason R B Dyck; Grzegorz Sawicki; Richard Schulz
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

2.  Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog.

Authors:  James A Stewart; Chih Chang Wei; Gregory L Brower; Patricia E Rynders; Gerald H Hankes; A Ray Dillon; Pamela A Lucchesi; Joseph S Janicki; Louis J Dell'Italia
Journal:  J Mol Cell Cardiol       Date:  2003-03       Impact factor: 5.000

3.  Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9.

Authors:  Anne M Romanic; Stephen M Harrison; Weike Bao; Cynthia L Burns-Kurtis; Susan Pickering; Juanli Gu; Evelyn Grau; Joyce Mao; Ganesh M Sathe; Eliot H Ohlstein; Tian Li Yue
Journal:  Cardiovasc Res       Date:  2002-06       Impact factor: 10.787

4.  Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload.

Authors:  Amanda L Chancey; Gregory L Brower; J Thomas Peterson; Joseph S Janicki
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

Review 5.  Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

Authors:  E E Creemers; J P Cleutjens; J F Smits; M J Daemen
Journal:  Circ Res       Date:  2001-08-03       Impact factor: 17.367

6.  Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.

Authors:  Stefan Blankenberg; Hans J Rupprecht; Odette Poirier; Christoph Bickel; Marek Smieja; Gerd Hafner; Jürgen Meyer; François Cambien; Laurence Tiret
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

7.  Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

Authors:  Merry L Lindsey; Joseph Gannon; Masanori Aikawa; Frederick J Schoen; Elena Rabkin; Lori Lopresti-Morrow; Jamie Crawford; Shawn Black; Peter Libby; Peter G Mitchell; Richard T Lee
Journal:  Circulation       Date:  2002-02-12       Impact factor: 29.690

8.  Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines.

Authors:  Mei Sun; M Anne Opavsky; Duncan J Stewart; Marlene Rabinovitch; Fayez Dawood; Wen-Hu Wen; Peter P Liu
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

9.  Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.

Authors:  Aernout Luttun; Esther Lutgens; Ann Manderveld; Katleen Maris; Désiré Collen; Peter Carmeliet; Lieve Moons
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

10.  Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed.

Authors:  J Orbe; L Fernandez; J A Rodríguez; G Rábago; M Belzunce; A Monasterio; C Roncal; José A Páramo
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

View more
  52 in total

Review 1.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

Review 2.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

Review 3.  Lymphocytes and the adventitial immune response in atherosclerosis.

Authors:  Kirsti A Campbell; Michael J Lipinski; Amanda C Doran; Marcus D Skaflen; Valentin Fuster; Coleen A McNamara
Journal:  Circ Res       Date:  2012-03-16       Impact factor: 17.367

4.  MMP9 inhibition increases autophagic flux in chronic heart failure.

Authors:  Shyam S Nandi; Kenichi Katsurada; Neeru M Sharma; Daniel R Anderson; Sushil K Mahata; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

5.  Novel Biomarkers: Utility in Patients with Acute Chest Pain and Relationship to Coronary Artery Disease on Coronary CT Angiography.

Authors:  Adefolakemi Babatunde; Asim Rizvi; Quynh A Truong
Journal:  Curr Cardiovasc Imaging Rep       Date:  2014-07

Review 6.  Pathophysiology of cardiovascular disease in diabetes mellitus.

Authors:  Gerardo Rodriguez-Araujo; Hironori Nakagami
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-02-14

Review 7.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

8.  Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

Authors:  Menggui Huang; Yanqing Gong; Jessica Grondolsky; Jane Hoover-Plow
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

Review 9.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

10.  Evaluation of the Effects of Aging on the Aorta Stiffness in Relation with Mineral and Trace Element Levels: an Optimized Method via Custom-Built Stretcher Device.

Authors:  Duygu Aydemir; Naveed Salman; Mehrdad Karimzadehkhouei; B Erdem Alaca; Belma Turan; Nuriye Nuray Ulusu
Journal:  Biol Trace Elem Res       Date:  2020-09-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.